Next Pharmaceuticals Acquires Rights to Sytrinol Heart-Health Ingredient
Research shows Sytrinol significantly improves total cholesterol, LDL cholesterol, and triglyceride levels up to 30%, 27%, and 34%, respectively.
Next Pharmaceuticals (Salinas, CA) has purchased the future worldwide distribution rights to Sytrinol, a patented ingredient aimed at heart health, derived from natural citrus and palm fruit extracts. Supplier Proprietary Nutritionals Inc. (Kearny, NJ) holds the distribution rights to Sytrinol until the end of this year. Next Pharmaceuticals will own the rights, including patents, trademarks, and scientific property, purchased from the ingredient’s Canada-based research and development firm KGK Synergize.
Sytrinol combines polymethoxylated flavones and delta-, gamma-, and alpha-tocotrienols.The companies say clinical research shows Sytrinol significantly improves total cholesterol, LDL cholesterol, and triglyceride levels up to 30%, 27%, and 34%, respectively, compared to placebo, as well as increases HDL cholesterol.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
